At GLI, we aim to keep you updated on the latest innovations and advancements in liver cancer. As we begin to approach Liver Cancer Awareness Month, take a look at our liver cancer resources that are available on our Liver Central website.
Liver Cancer Awareness Month is just around the corner! This October, join GLI for our annual #OctoberIs4Livers campaign, where we’ll be accompanied by special guests during GLI LIVE and our Liver Cancer Lessonsseries, welcome patients around the world to learn about liver cancer during our Open House series, and much more! Also, take a look at our toolkit to share more information about liver cancer with your family and friends. If you’d like to represent our campaign during October, please checkout our merch!
HEPATIC (HCC Workshop)
The third and final HEPATIC (HCC Education and Protocols to Advance Treatment through Integrated Collaboration) training was held on August 26, 2023 in San Diego, CA. Attendees joined GLI’s Sarah Manes and other oncology experts to connect with their clinical care community, discover the most accurate recommendations for treating patients with HCC, and learn about the importance of multidisciplinary care. Thanks to the France Foundation for their collaboration and partnership on this important educational opportunity.
Genetic Marker Linked to Drug-Resistant Liver Cancer
Out of the 35,000 annual liver cancer cases diagnosed in the United States, one-fourth of hepatocellular carcinoma cases cannot be treated surgically. Patients who do not qualify for a tumor resection or a liver transplant often take lenvatinib to hinder tumor growth, though many patients have developed a resistance. Recently, researchers at the UT Southwestern Medical Center have discovered a genetic marker that can aid physicians in predicting which patients are more susceptible to lenvatinib resistance. Read more.
Cancer Experts at Jersey Shore University Medical Center Implanting First Targeted Liver Tumor Treatment Pumps in Patients
Jersey Shore University Medical Center is making great strides in the treatment of advanced primary liver cancer, such as intrahepatic cholangiocarcinoma. This new state-of-the-art technology is a palm-sized hepatic artery infusion pump that is placed in the abdomen to deliver continuous chemotherapy. Since the treatment is delivered directly to the liver, patients do not experience the same negative side effects or toxicities that stem from traditional chemotherapy. Read more.
Cancer Moonshot Scholars
The National Cancer Institute has announced their new efforts to include underrepresented populations into their clinical trials. Participants in trials for new treatments have been overwhelmingly white, which does not accurately reflect drug response for the diverse population of patients with liver (and other) cancers. The Cancer Moonshot Scholars program is designed to advance cancer research and improve the diversity of clinical trial participants. Read more.
A3: The Learning Experience
Washington DC, September 30 – October 2, 2023
Liver patients, their loves ones, and clinician advocates will be gathering in Washington, DC, at the end of the month to gain critical knowledge and skills for effective liver patient advocacy! Experts in the following topics will equip advocates to effect change in their communities: liver health basics, techniques in media and storytelling, the research and development process, health insurance and coverage, collaboration with policymakers, and more!
It’s not only important to GLI to keep you updated; we value your input and updates. This is a reminder to Liver Cancers Council members and supporters to share news to be featured in our monthly newsletter or on our Liver Central website.